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Point-of-care photonic 
biosensors could promote 
more integrated, informative, 
timely and precise diagnoses 
of human diseases—and 
better-targeted health care.
Nanophotonic interferometric biosensor for multiplexed 
analysis of protein and nucleic acid biomarkers. 
Dámaso Torres/ICN2
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W
e live amid the rise of precision medi-
cine. Every day seems to bring news 
of the discovery and implementation 
of novel treatments to eradicate dis-
eases, and personalized therapies to 
att ack malignancies with impressive results. Scientists 
around the world are on a quest for the key remedies 
to reduce the burdens of cancer and of cardiac, degen-
erative or autoimmune disorders. But fi rst things fi rst: 
To fi ght a disease, fi rst we need to fi nd it.
Early, accurate and informative diagnosis is essential 
for selecting the most appropriate therapy and admin-
istering it in time. Rapid identifi cation of an infectious 
outbreak is crucial to stem an epidemic; early-stage detec-
tion of cancer holds extreme importance for treatment 
response and patient survival. Clinical diagnosis thus 
must evolve even more to incorporate new methods and 
technologies that enable rapid, simple screening of the 
population, to detect diseases before their physical onset.
These new diagnostic techniques will need to identify 
remote biological disorders that might carry pathologi-
cal consequences—providing information about the 
disease stage and severity, and the most promising 
drug or treatment candidates. And, ideally, diagnostic 
systems should be small, portable devices that can be 
employed directly by those who need it: physicians, 
pharmacists or the patients themselves.
Photonic biosensors: SPR and beyond
One of biomedicine’s best assets in this endeavor is 
biosensors. These are self-integrated devices that use 
specifi c biorecognition elements—such as antibodies, 
DNA strands or enzymes—to capture and detect a 
target molecule, or analyte, present in a sample. This 
interaction produces a variation in an electrical, opti-
cal or mechanical property of the transducer that can 
be read and directly related to the amount of analyte.
Photonic biosensors exploit light’s unique proper-
ties to realize some of the more sensitive, robust and 
reliable sensing platforms currently available. The 
paramount example is the surface plasmon resonance 
(SPR) biosensor. This system, based on an optical 
phenomenon discovered between 1902 and 1912, was 
fi rst sold as an analytical technology in 1990. After 
30 years, SPR biosensors have emerged as routine 
analysis platforms in many research and pharma-
ceutical laboratories, commercialized worldwide. 
Importantly, they have served as a solid foundation 
for the investigation and development of new nano-
photonic technologies that move beyond existing 
biosensors and expand their capabilities.
Yet, despite the impressive ability for nanoscale 
control and the vast knowledge and expertise in bio-
analysis that have arisen in recent years, the optimum 
nanophotonic biosensor for point-of-care clinical diag-
nosis has remained elusive. Where do the limitations 
lie—and why have optical biosensors been slow to make 
their way into the clinic? 
In this feature, we overview some of the latest 
advances in nanophotonic technologies for biosensing, 
the main challenges and limitations, and current pros-
pects. We will also look at some promising applications 
of nanophotonic sensors in biomedicine, highlighting 
their unique capabilities and their potential to revo-




In a typical nanophotonic biosensor, nanostructures on the sensor 
strongly enhance the incident light field; changes in refractive index at 
the interface due to biorecognition events (for example, antibody–antigen 
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The evanescent field and its sensitivity
Most common optical biosensors are based on the 
so-called evanescent-fi eld principle, generally using 
nanoplasmonics and silicon-photonics nanotechnology. 
Evanescent-fi eld biosensors can detect biomolecular inter-
actions occurring at the sensor surface, in real time and 
without labels or dyes, thereby off ering a rapid, simple 
and noninvasive technique for studying biochemical 
processes or quantifying analytes. 
Plasmonic biosensors employ nanometer-sized metal-
lic fi lms or nanostructures (mainly gold), which absorb 
incident electromagnetic radiation and excite coherent 
electron resonances (surface plasmon polaritons) at 
the surface. This resonance can either propagate along 
the thin fi lm (propagating SPR) or be confi ned to the 
vicinity of the nanoparticle (localized SPR, or LSPR). 
Either way, it generates a strong near-fi eld enhance-
ment that penetrates a few nanometers (10–500 nm) 
into the surroundings.
This evanescent fi eld is highly sensitive to refrac-
tive-index variations in the medium. Thus, a change 
of composition or mass at the metal–dielectric inter-
face translates directly to a variation of the intensity, 
wavelength, angle or phase of the light. The real-time 
interrogation of such variations during a biorecognition 
event (for example, an antibody–antigen interaction) 
provides quantitative information about both the 
molecule’s concentration and the affi  nity and kinetic 
parameters of the biomolecular interaction.
The detection limit for nanoplasmonic biosensors 
ranges from 10–5 to 10–7 refractive-index units (RIU), 
equivalent to detection at the nanomolar (nM) level for 
biomolecular analysis. Demonstrations in recent years 
have highlighted the great analytical performance 
of these biosensors, with an exponential increase of 
publications and patents of new sensing systems for 
disease diagnostics. These systems can detect proteins, 
nucleic acids and pathogens in a few minutes, without 
the need of fl uorescent or colorimetric tags—and with 
high accuracy. 
From plasmonics to silicon photonics
For detecting very low amounts of biomarkers, how-
ever, the sensitivity of nanoplasmonic biosensors can 
be limited—or they can require light-coupling schemes 
that complicate their integration and miniaturiza-
tion. In these cases, silicon-nanophotonics technology 
may off er a powerful alternative. Biosensors based on 
Photonic biosensors exploit light’s unique properties to 
realize some of the more sensitive, robust and reliable sensing 
platforms currently available.
A nanoplasmonic sensor
Example of a nanoplasmonic biosensor that uses a surface 
dotted with gold nanodisks. Courtesy of the authors 
Comparison of state-of-the-art 
nanophotonic biosensors
RI detection  Mass detection
 Biosensor limit (RIU) limit (pg/mm2)
Nanoplasmonics 10–5–10–7 0.1–1
Grating couplers 2×10–6 0.3
Micro-ring resonators 10–5–7×10–7 1.5–3
Photonic crystals 10–5 0.4–7.5
 Mach-Zehnder interferometer 10–7–2×10–8 0.01–0.06
Young interferometer 6×10–8–9×10–9 0.01–0.75
 Bimodal waveguide interferometer 10–8 0.01
Silicon wires 2×10–6 0.25
Slot waveguides 10–6 0.9–16
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silicon resonators or waveguides also work through 
an evanescent-field principle, and in some cases their 
sensitivity can outperform that of their nanoplasmonic 
counterparts by more than two orders of magnitude.
In particular, interferometric sensors today constitute 
the most sensitive technology available, with detec-
tion limits of up to 10–8 RIU. These sensors consist of a 
waveguide that is partly exposed to a sensing area and 
partly used as reference. The evanescent field generated 
along the waveguide probes the refractive-index changes 
occurring at the sensing area, producing a difference 
in the phase of the light. When recombined, the inter-
ferometric signal obtained can be correlated with the 
analyte concentration, as with nanoplasmonic sensors.
Interferometric biosensors have also been applied 
in clinical diagnostics, showing sensitivities for 
biomolecular markers in the picomolar to attomolar 
(pM–aM) range without any labelling or amplification 
steps. Moreover, the use of silicon technology implies 
an intrinsic potential for producing photonic integrated 
circuits (PICs) for possible incorporation into miniatur-
ized lab-on-a-chip (LOC) sensing systems. 
At the level of the lab, evanescent-field-based bio-
sensors have shown the analytical and technological 
capabilities to become the next-generation diagnostic 
systems—they have demonstrated excellent performance 
and versatility, achieved outstanding detection limits, 
and shown promise for label-free, real-time analysis 
of all types of clinical biomarkers. Clinical settings, 
though, demand “black box” devices that can operate 
in point-of-care settings with the same accuracy and 
reliability as in the lab. It’s a significant challenge—how 
do we get there?
Engineering compact,  
ready-to-use biosensors
In one sense, the answer is simple: Miniaturize every-
thing—but also automate it, simplify it and make it 
clinically reliable. But, as always, the devil is in the details.
The objective of point-of-care diagnostic biosen-
sors is fully operational, portable devices that can be 
readily employed by end-users. Biosensors in clinical 
settings must analyze human samples like blood or 
urine directly, without pretreatment, providing unam-
biguous responses about the levels of specific molecules 
with an exquisite accuracy, selectivity and reproduc-
ibility. Multiplexed assays—the simultaneous detection 
of different markers from the same sample—are also a 
requirement for rapid, truly informative diagnostics.
To meet these demands, research in 
nanophotonic biosensors has expanded 
to include integration with aspects 
of the systems that contain them.
Advanced microfluidic systems
Microfluidics engineering has 
evolved tremendously over the last 
decade, in part thanks to progress in 
micro- and nanofabrication techniques 
The bimodal waveguide (BiMW) technology devel-
oped by the Nanobiosensors and Bioanalytical 
Applications Group in Barcelona is one example 
of an interferometric biosensor.
Olalla Calvo-Lozano
Examples of nanophotonic  
biosensors integrated in  
microfluidic systems.
Top: Courtesy of the authors / Right:  
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The objective of point-of-care diagnostic biosensors is fully 
operational, portable devices that can be readily employed 
by end-users. 
that enable production of miniaturized polymer car-
tridges providing full and automated control of fl uid 
transport. The latest microfluidic systems include 
hydraulic or pneumatic valves that can control multiple 
channels; microreactors; integrated pumps and waste 
reservoirs; and other elements.
These LOC devices can be automated and remotely 
controlled by software, which dramatically mini-
mizes sample handling and manipulation by the 
user and scales down the biosensor system’s overall 
footprint. Other strategies for on-chip fl uid manipula-
tion take advantage of capillary action and material’s 
hydrophilicity; centrifugal forces (as in the case of 
compact-disc microfl uidics); or even electrochemistry 
(in digital microfl uidic systems). The latt er is espe-
cially interesting, since it enables fl uid transportation 
and mixing using nanoliter-volume droplets, which 
dramatically reduces the sample volume required 
for the analysis. 
Integration in handheld devices
Current research also focuses on the integration of 
all optical components into miniaturized platforms, 
and their transfer from laboratory optical tables to 
small, portable devices. Replacing lasers, microscopes 
and spectrometers by LEDs and CMOS detectors can 
allow compact devices with reasonable performance 
to be realized.
Here, optical-biosensor development has exploited 
the breakthrough of extremely powerful smartphones. 
Nanoplasmonic sensors have been adapted to employ 
the fl ash LED lights and the high-quality cameras of 
commercial smartphones for operation as simple external 
accessories. Although these devices can’t boast the ana-
lytical sensitivity of conventional laboratory platforms, 
they off er the promise of truly portable point-of-care 
diagnostic systems.
Solving and simplifying in-coupling of light for 
these compact platforms, and providing high-through-
put readouts from them, remain ongoing challenges. 
Imaging 2D microarrays at relatively large scales often 
results in crosstalk issues or low signal-to-noise ratios. 
In waveguide-based biosensors, for example, coupling 
Toward personalized therapies
The design of novel diagnostics based on nanophotonic sensing technology is open-
ing new avenues for personalized medicine. 
Optical label-free biosensors for direct, real-
time analysis of biomolecular interactions can 
be further exploited in biomedical research to 
boost the development of precise and individual-
ized therapies for serious diseases, like cancer 
or autoimmune disorders, and to facilitate the 
widespread administration of such personalized 
approaches.
Recent efforts have started to address this 
complex but far-reaching goal. Nanophotonic 
biosensors have been already described for the 
label-free analysis of cell regulation pathways, 
as well as for so-called epigenetic alterations, 
such as DNA methylation or alternative splic-
ing events. Such events have been suggested as 
potential targets for the earliest possible detec-
tion of tumor-initiating processes as well as for 
precision therapeutics. Direct, label-free analysis 
of such genomic disorders in pre-tumor cells 
affords an opportunity for developing population-
screening techniques with diagnostic, prognostic 
and therapeutic information outputs that could 
substantially reduce the cancer burden.
Likewise, optical label-free biosensors 
have been reported as potential alternatives 
for live-cell analysis, which could facilitate 
implementation of novel personalized can-
cer treatments. Recently discovered cell-based 
immunotherapies, like the CAR-T cell therapy, 
might greatly benefit from devices able to achieve 
single-cell sensitivities and to monitor, in real 
time, the activity of bioengineered immune cells 
without labelling or staining. Such 
nanophotonic biosensors, 
if realized, could help 
bring down currently 
exorbitant treatment 
costs and speed up 
the administration of 
powerful immuno-
therapies to cancer 
patients worldwide.
30        OPTICS & PHOTONICS NEWS  APRIL 2020
the light from macrometric sources to multiple submi-
cron waveguides in parallel is an arduous task.
To get past these problems, new nanophotonic 
designs incorporating gratings, photonic crystals or 
integrated tapers, which may offer an efficient and 
cost-effective solution, should be investigated and imple-
mented in the sensor fabrication process. Also worth 
researching could be data processing and machine 
learning, to enhance the acquisition and use of opti-
cal signals by boosting the signal-to-noise ratios and 
minimizing crosstalk for multiplexed assays, thereby 
providing fast, clear and precise information for the 
clinical diagnosis.
Surface chemistry and sample treatment
Surface biofunctionalization is crucial in biosensor 
development. To achieve high detection sensitivity, 
selectivity and reproducibility, the target bioreceptor 
must be appropriately anchored to the sensor trans-
ducer. Parameters such as the receptors’ density and 
orientation  and the anti-fouling properties of the sens-
ing surface must be carefully controlled to enhance 
the biosensor’s analytical performance and ensure its 
operational reliability.
Numerous surface-chemistry strategies—such as 
covalent binding to functional monolayers of alkane-
thiols or silanes, or employing affinity-ligands such as 
the biotin–streptavidin pair—are widely used to accom-
plish these goals. However, these procedures need to 
be optimized for each specific application, depending 
on the nature, size and properties of the bioreceptor 
and the target analyte. Some new research perspectives 
envision overcoming those pitfalls through a universal-
surface chemistry strategy, suitable for the detection of 
different types of biomarkers, like proteins, nucleic acids 
and pathogens. The development of multifunctional 
macromolecules, synthetic polymers and 2D materi-
als could offer interesting alternatives to serve as the 
interface for bioreceptor immobilization.
Finally, the “nightmare scenario” of evanescent-
field biosensors working in label-free format—and, yet, 
a key ultimate goal of such sensors—is direct analysis 
of human samples, like blood or urine. The large con-
centration of non-relevant molecules present in these 
fluids, together with the huge variability of samples 
from different patients, generally results in false-positive 
or false-negative analytical results. The solution to this 
challenge may lie in combining efficient anti-fouling 
surface coatings with integrated on-chip sample pro-
cessing (for example, filtration membranes) that could 
be automated to ensure a rapid, reliable analysis.
Toward accurate, informative  
and early diagnosis
The vast majority of the clinical diagnosis applications 
developed for optical biosensors target the quantifica-
tion of disease-specific circulating biomarkers. Classic 
examples are the detection of C-reactive protein (CRP) 
and cytokines, like interleukins or interferons, for inflam-
matory disorders, or of the carcinoembryonic antigen 
(CEA), the prostate specific antigen (PSA) and the p53 
protein (among others) for cancer diagnosis. Also, DNA 
mutations of specific genes, like BRCA1 and BRCA2, 
have been extensively targeted for the detection of 
breast cancer. Still other optical biosensors, developed 
for infectious diseases, often target direct detection 
and identification of the pathogen, such as the bacteria 
Escherichia coli or Staphylococcus aureus.
Recently developed photonic biosensors aim at still 
more advanced and improved diagnosis, targeting 
novel biomarkers for accurate, early disease detection 
and providing specific information related to prognosis 
and optimum therapy. We close this feature by looking 
at a number of areas where nanophotonic biosensors 
could help change the game.
MicroRNAs. MicroRNAs are small, non-coding nucleic 
acids that circulate in body fluids in very low con-
centration, but whose specific levels are strongly 
M. Cruz Cardenosa-Rubio (left) and Olalla Calvo-Lozano 
(right) working with a small benchtop SPR system 
developed in the laboratory.
Maria Soler
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Nanophotonic biosensors are fast becoming a versatile, 
powerful technology with exceptional potential for upgrading 
diagnostics—and improving global health care and well-being. 
associated with pathological disorders. Direct detec-
tion and quantification of microRNA panels with 
multiplexed optical biosensors could become a highly 
precise screening technique for the early diagnosis 
of several cancers.
Some first steps have already been made toward that 
goal. A bimodal waveguide (BiMW) interferometric sen-
sor has achieved ultrasensitive detection of such small 
nucleic-acid chains, identifying microRNA-181 in urine 
of bladder cancer patients, with a limit of detection of 
only 23 aM in less than 20 minutes in a direct assay. 
Micro-ring resonator arrays have also been employed 
for the multiplexed analysis of eight microRNAs from 
surgical glioma cells.
Autoantibodies. Likewise, new protein biomarkers 
have been described for early cancer diagnosis. Solid 
tumors in particular, like lung, breast or colorectal 
cancer, can trigger immune reactions in the patient, 
releasing specific antibodies into the bloodstream. 
These so-called autoantibodies appear and increase 
their levels at the initial stages of tumor development, 
even before the physiological onset of the illness. 
Nanoplasmonic biosensors have recently been devel-
oped to target different cancer-related autoantibodies, 
achieving adequate limits of detection in serum and 
plasma samples.
Bacterial detection. Infectious-disease diagnosis could 
present still another opportunity for optical label-free 
biosensors. Bacterial infections, if not promptly identi-
fied and suitably treated, can be extremely dangerous, 
in some cases even ending with a sepsis shock, in which 
the infection rapidly spreads to the whole body, a fatal 
development for the patient. Sepsis is actually the main 
cause of death in intensive care units (ICUs), with a 
mortality of 40%–50% due to delayed diagnosis and 
inappropriate antibiotic therapy.
Biosensors able to detect and precisely identify a 
bacterial infection in a few minutes are essential to 
minimize this burden. Further, the ideal biosensor 
should be able to analyze in situ the specific bacte-
ria, and provide information on possible antibiotic 
resistance, giving clues for the correct treatment. Here, 
ongoing research has already achieved significant 
results. Nanophotonic biosensors have been reported 
for bacterial analysis (for example, for S. aureus) with 
limits of detection between 4 and 10 colony-forming 
units (cfu) per milliliter. These sensors can even 
accurately differentiate methicillin-resistant (MRSA), 
methicillin-susceptible (MSSA) and borderline oxa-
cillin-resistant (BORSA) S. aureus strains in less than 
20 minutes. Other reported nanoplasmonic sensors 
can work in multiplex format, identifying two or more 
different bacteria species.
Routine monitoring. Finally, portable, user-friendly point-
of-care biosensors might be very interesting for routine 
therapy monitoring and follow-up. Nanoplasmonic 
biosensors have been developed for monitoring of the 
drug acenocoumarol, an anticoagulant employed for 
thromboembolic disorders, and for adalimumab, pre-
scribed for Crohn’s disease, as well as for follow-up on 
gluten-free diets for patients with celiac disease.
As these examples suggest, nanophotonic label-
free biosensors are fast becoming a versatile, powerful 
technology with exceptional potential for upgrading 
diagnostics—and thereby improving global health care 
and well-being. OPN
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